Neural Therapeutics - How do we prevent people getting addicted to opioids?
London, UK
|
May 20, 2024 09:00 AM Eastern Daylight Time
Neural Therapeutics CEO Ian Campbell is answering some of the questions raised by Scientific Advisor Professor David Nutt's presentation on the potentially revolutionary untapped effects of psychedelic medicine.
Today's questions asks: "The opioid crisis has touched every sector of society and shows no sign of stopping. How do we prevent more people from becoming addicted?"
He emphasised that contrary to common concerns, the substances developed by the company have not shown addictive properties in clinical trials. Campbell highlighted that there is no evidence of withdrawal symptoms in patients. Moreover, ongoing scientific work supports the effectiveness of these substances in treating individuals with substance use disorders.
The presentation focused on what Professor Nutt describes as the utility of psychedelic compounds and their potential to transform the treatment of mental illness.
To watch the full presentation, click here: https://www.proactiveinvestors.co.uk/companies/news/1035785/professor-david-nutt-presents-his-insights-into-psychedelic-medicine-neural-therapeutics-1035785.html
Neural Therapeutics is a drug-discovery company focusing on plant-based active substances with the goal of delivering beneficial, over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments where no significant treatment is available today.
Contact Details
Proactive United States
+1 347-449-0879
